A safety evaluation of allogeneic freeze-dried platelet-rich plasma or conditioned serum compared to autologous frozen products equivalents in equine healthy joints.
Authors: Garbin Livia Camargo, Contino Erin K, Olver Christine S, Frisbie David D
Journal: BMC veterinary research
Summary
# Editorial Summary Autologous platelet-rich plasma and conditioned serum have emerged as promising biological therapies for equine musculoskeletal conditions, yet their clinical utility is hampered by batch-to-batch cytokine variability, the requirement for patient donation, and dependence on costly cold-chain storage—limitations that restrict field availability and standardisation. Garbin and colleagues investigated whether allogeneic freeze-dried versions of these products could overcome these practical barriers by evaluating their safety profile in healthy equine joints, following encouraging preliminary laboratory data. Using horses as a translational model, the researchers compared intra-articular administration of allogeneic freeze-dried conditioned serum and PRP against their autologous frozen equivalents, measuring local and systemic inflammatory responses, clinical safety outcomes, and joint integrity over the study period. The freeze-dried allogeneic formulations demonstrated comparable safety profiles to autologous products, with no unexpected adverse reactions or exaggerated inflammatory responses in healthy joints. These findings suggest that standardised, shelf-stable allogeneic products merit further investigation as clinically viable alternatives that could significantly improve accessibility and consistency of biological therapies in equine practice, though efficacy in naturally occurring pathology remains to be demonstrated.
Read the full abstract on PubMed
Practical Takeaways
- •Allogeneic freeze-dried products could streamline field use by eliminating the need for autologous collection, processing delays, and ultra-cold storage requirements
- •Safety evaluation in healthy joints provides baseline data before considering therapeutic use in clinical osteoarthritis cases
- •If safety confirmed, practitioners could stock ready-to-use hemoderivative products rather than managing individual autologous harvesting for each patient
Key Findings
- •Allogeneic freeze-dried PRP and conditioned serum were evaluated as safer alternatives to autologous products for intra-articular use in healthy equine joints
- •Study compared safety profiles of allogeneic freeze-dried hemoderivatives versus autologous frozen equivalents using horses as a translational model
- •Freeze-dried allogeneic products offer practical advantages including immediate availability and room-temperature storage compared to autologous products requiring low-temperature storage